Milind Deshpande Purchases Spero Therapeutics Shares
Milind Deshpande acquired 20,000 shares of Spero Therapeutics on June 23, 2026.
Key Points
- Milind Deshpande bought 20,000 shares of Spero Therapeutics on June 23, 2026, without a planned trading scheme.
- Shares of Spero Therapeutics traded near $2.02 on Friday, with a market cap of $116.9 million and a P/E ratio of 7.48.
- Insider buying included multiple executives, and analysts from HC Wainwright reiterated a buy rating with a $5.00 target.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Milind Deshpande made a notable move by buying 20,000 shares of Spero Therapeutics, Inc. (NasdaqGS: SPRO) on June 23, 2026. This insider transaction was not part of a pre-planned trading scheme, highlighting a direct investment in the company's future.
Insider Buying and Selling at Spero Therapeutics, Inc.
On June 23, 2026, several insiders, including Milind Deshpande, purchased shares of Spero Therapeutics. Milind Deshpande, along with Jackson Scott Thomas, John Pottage Jr., Cynthia Smith, Patrick V.J.J. Vink, and Frank Thomas, each acquired 20,000 shares. These purchases were made outside of any pre-planned trading programs.
Spero Therapeutics, Inc. Stock Up 68.3%
Shares of Spero Therapeutics were trading near $2.02 on Friday. The company, with a market cap of about $116.9 million, has a P/E ratio of 7.48, indicating a relatively low valuation compared to its earnings. Over the past year, the stock has ranged from a low of $1.80 to a high of $3.22, with a 50-day moving average of $2.63 and a 200-day moving average of $2.40. Spero's financial health is underscored by a strong current ratio of 10.50 and a quick ratio of 10.23, though it carries a debt-to-equity ratio of 4.67.
$SPRO stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have shown interest in Spero Therapeutics, with HC Wainwright & Co. maintaining a 'buy' rating and setting a price target of $5.00 on January 30, 2025. The consensus among analysts is a 'hold' recommendation, with an average target price of $4.00.
About Spero Therapeutics
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing new treatments for multi-drug resistant bacterial infections and rare diseases. Headquartered in Cambridge, Massachusetts, the company is led by CEO Esther P. Rajavelu and employs around 25 people. Spero's leading product candidate, Tebipenem HBr, is an oral antibiotic aimed at treating complicated urinary tract infections. The company has strategic partnerships for the development and commercialization of its products in various international markets.
Bottom Line
Milind Deshpande's recent share purchase signals confidence in Spero Therapeutics' potential. Investors often monitor such insider activities for insights into a company's prospects. However, it's important to remember that insider transactions are just one piece of the puzzle. Spero's stock performance and analyst ratings provide additional context for evaluating its market position.
Get Spero Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SPRO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.